Welcome to our dedicated page for Marker Therapeut SEC filings (Ticker: MRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Marker Therapeutics, Inc. (Nasdaq: MRKR), a Houston-based clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. These regulatory documents offer detailed insight into the company’s financial condition, governance, and clinical and corporate milestones.
Through Marker’s periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can examine financial statements, grant income from U.S. state and federal agencies, research and development spending related to programs like MT-601 and MT-401-OTS, and discussions of risks associated with clinical-stage biotechnology operations. Current reports on Form 8-K disclose material events, including clinical updates from the Phase 1 APOLLO study in relapsed lymphoma, initiation of the Off-the-Shelf MAR-T program in AML and MDS, financial results for specific quarters, changes in the company’s independent registered public accounting firm, and appointments to the board of directors.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping users interpret complex disclosures without reading every line of each document. Real-time updates from the SEC’s EDGAR system ensure that new MRKR filings, including 8-Ks describing clinical or corporate developments, are available promptly. Users can also review exhibits attached to filings, such as press releases and presentations referenced in 8-Ks, to understand how Marker communicates its MAR-T platform progress and strategic decisions.
For investors researching MRKR stock, this page offers a structured view of Marker Therapeutics’ regulatory history, from financial reporting and auditor changes to clinical trial disclosures and governance updates, with AI tools that highlight the most relevant information in each filing.
Marker Therapeutics, Inc. reported several financing and grant developments and ongoing clinical spending. The company sold 1,624,075 shares under an ATM between July 17-21, 2025 for net proceeds of $4.5 million at an average $2.87 per share. A private placement closed December 23, 2024 generated approximately $14.9 million of net proceeds. Multiple grants supported R&D: CPRIT AML and pancreatic grants (noted amounts include $11.0 million and $9.5 million grants), an FDA Orphan Products Grant ($2.0 million, $1.1 million received to date), SBIR and NIH awards, and other grants producing recorded grant income and receivables ranging from $0.012 million to $1.3 million. As of June 30, 2025, the company reported $1.9 million in cash (including $1.4 million restricted) and $9.9 million in U.S. government agency securities for aggregate cash, cash equivalents, and restricted cash of $11.8 million, down from $19.2 million as of December 31, 2024. The company granted equity awards (CEO: 50,000 options; non-employee directors: 30,000 options each) at $1.59 strike and disclosed licensing obligations that include royalty payments and up to $64.85 million of potential milestone payments to BCM.
Marker Therapeutics disclosed a change in its independent registered public accounting firm: Marcum LLP resigned and CBIZ CPAs P.C. was engaged to serve as the companys auditor for the year ending December 31, 2025, effective with the review of the condensed consolidated financial statements for the quarter ended June 30, 2025. The engagement was approved by the Board of Directors and CBIZ will perform services previously provided by Marcum.
Marcums audit reports for the years ended December 31, 2024 and 2023 did not contain an adverse opinion or disclaimer and were not qualified, except that they included an explanatory paragraph expressing substantial doubt about the companys ability to continue as a going concern. The filing states there were no disagreements and no reportable events between the company and Marcum during the periods covered. A letter from Marcum is filed as Exhibit 16.1.
Marker Therapeutics, Inc. (Nasdaq: MRKR) filed Prospectus Supplement No. 2 to its November 2018 resale registration statement. The sole purpose is to update the “Selling Stockholders” table after John R. Wilson transferred his holdings to the John R. Wilson Revocable Trust U/A DTD 08/03/2017, for which he is sole trustee. The trust now appears as a substitute selling stockholder.
- Shares affected: 781,200 common shares (post-1:10 reverse split) are beneficially owned; up to 606,078 shares (≈0.54 m) are registered for resale; 175,122 shares would remain if the entire allotment is sold.
- Ownership impact: The trust currently controls 1.5 % of MRKR’s 11,314,835 outstanding shares (as of 30 Jun 2025). Percentage falls to ~0.2 % post-sale.
- Capital effects: These are already-issued shares—no new dilution to existing shareholders. However, resale could increase float and near-term supply.
- Price reference: Last reported price on 4 Aug 2025 was $1.24.
- Governance note: Mr. Wilson, a former director, resigned 24 Jan 2025; disclosure aligns holdings with current status.
All other terms, risk factors and the plan of distribution in the original prospectus remain unchanged.